Genscript Biotech (1548.HK) Earnings Analysis
Genscript Biotech (1548.HK) next reports earnings on 2026-08-17, consensus EPS -0.07836 HKD. Last quarter (2026-03-15) it beat with EPS -0.23354 HKD vs -0.23354 HKD est (0%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -8.15.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1548.HK next report earnings?
| Next earnings date | 2026-08-17 |
|---|---|
| Consensus EPS estimate | -0.07836 HKD |
| Revenue estimate | 3.00B |
1548.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-15 | -0.23354 HKD | -0.23354 HKD | 0% | Beat |
| 2025-08-17 | -0.0927 HKD | 0.628 HKD | -114.8% | Miss |
| 2025-03-11 | 11.5 HKD | -0.07771 HKD | +14898.6% | Beat |
| 2024-08-11 | -0.64589 HKD | n/a | n/a | n/a |
| 2024-08-09 | -0.64594 HKD | -0.07811 HKD | -727% | Miss |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
1548.HK valuation and analyst view
| Trailing P/E | -8.15 |
|---|---|
| Trailing EPS | -0.24444 HKD |
| Price / book | 1.13 |
| Dividend yield | 0.00% |
| Market cap | 34.13B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Genscript Biotech (1548.HK)'s next earnings date?
Genscript Biotech is next scheduled to report on 2026-08-17, with a consensus EPS estimate of -0.07836 HKD and revenue estimate of 3.00B.
Did 1548.HK beat earnings last quarter?
In its 2026-03-15 report, 1548.HK posted EPS of -0.23354 HKD versus a -0.23354 HKD estimate — a beat of 0%.
What is 1548.HK's earnings track record?
Over the last 4 reported quarters with consensus data, 1548.HK beat estimates 2 times (50%).
What is 1548.HK's current P/E ratio and EPS?
1548.HK trades at a trailing P/E of -8.15 on trailing EPS of -0.2444398898363738 HKD.
What do analysts rate 1548.HK?
1548.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.